Illumina, Inc. (NASDAQ:ILMN)’s business accelerator focused on creating an innovation ecosystem for the genomics industry, has selected three new startups for its second funding cycle.
Led by Amanda Cashin, Ph.D., Illumina Accelerator aims to advance genomics by lowering the barrier to entry and expedite the time to market for entrepreneurs and early-stage companies that are working on scientifically and commercially promising next-generation sequencing applications.
The selected startups for the spring 2015 funding cycle of Illumina Accelerator are:
– PathoGn, Inc. an infectious disease platform company based in California using genomics and machine learning to build pathogen diagnostics and disease forecasting products for agricultural applications.
– Biome Makers Inc., a microbiome company founded by The Wine Guys, from Castile and Leon, Spain, introducing advanced genomics in the wine sector.
– Urology Diagnostics Incorporated, a genomics company from Oregon developing noninvasive urine sequencing diagnostics for screening and monitoring cancer.
They follow first graduates including Encoded Genomics, Inc., EpiBiome, Inc., and Xcell Biosciences, Inc.
Each startup will receive seed investment, a subscription to Illumina’s NextBio translational genomics database, access to match funding through the $40m Illumina Accelerator Boost Capital, and Illumina’s sequencing systems and reagents. In addition, they will gain access to business guidance and operational lab space in the San Francisco Bay Area during the six-month funding cycle.
Applications for the the Fall 2015 funding cycle are due by September 1, 2015. To apply, visit www.illumina.com/accelerator.